Addressing Unmet Needs in MS:

An Innovation Challenge

June 12-13, 2019

Celgene Headquarters, Summit, NJ

Applications were open through Monday, April 15, 2019 at 11:59 PM EDT

ABOUT THE INNOVATION CHALLENGE & AWARD


The Innovation Challenge will take place in June 2019 and will be open to Patient Entrepreneurs—those who have been affected by multiple sclerosis (MS) as either a patient, loved one or support partner—whose companies are helping develop solutions to address an unmet need in MS.  The goal of the initiative is to seek new solutions, beyond therapy, to help address either challenges faced by people with MS in their daily lives or an unmet need that could potentially improve outcomes and experiences for both people with the disease and their support partners.

Celgene will host Addressing Unmet Needs in MS: An Innovation Challenge, in Summit, New Jersey for the Challenge finalists, where a panel of judges, including healthcare professionals, patients and patient advocates, business leaders and industry experts, will award a $25,000 monetary grant to the most innovative, impactful business addressing an unmet need in MS.

Finalists will receive an invitation to Celgene headquarters to pitch their solutions.

Beyond presenting their innovative ventures to this group for a monetary grant, the finalists will also have the opportunity to exchange ideas on how to further advance patient innovation in the MS community; engage with Lyfebulb founders, Celgene leadership, representatives from the patient community, key opinion leaders and potential investors; and share insights with each other.

The Lyfebulb–Celgene Innovation Challenge stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features individuals who have created a product and a company based on issues encountered due to their personal experiences with a chronic illness (through their own diagnosis or that of a loved one).

Judging Criteria


Submissions should focus on new solutions, beyond therapy, that help address either challenges faced by people with MS in their daily lives or an unmet need that could potentially improve outcomes and experiences for both people with the disease and their support partners.

The judging panel will assess the following:

  • What is the strategic basis for the identified problem/gap (e.g., research conducted)?
  • How is the problem/gap being specifically addressed?
  • Does the innovation have the potential to improve the lives of people affected by multiple sclerosis?
  • What level of impact will the innovation make?
  • How will the impact on patient needs be measured?
  • How is the project or service unique to the market?
  • Feasibility of development and implementation into the marketplace (e.g., funding, regulations, requirements for testing)

Agenda


More information to come soon

The Judges


More information to come soon

Apply for the innovation challenge


Lyfebulb-Celgene Innovation Challenge & Award application (Closed)

Finalists will be provided an expenses-paid trip to Celgene headquarters to present their innovative solution addressing an unmet need in MS. One entrepreneur will be awarded the 2019 Lyfebulb-Celgene Innovation Award, including a $25,000 monetary grant to grow their company. Applicants must be a Patient Entrepreneur (someone who has been affected by MS either as a patient, loved one or support partner). Applications were open through Monday, April 15, 2019 at 11:59 PM EDT.

Sorry. This form is no longer available.

Lyfebulb

Lyfebulb-Logo

Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, IBD, and multiple sclerosis.

Celgene

Celgene-Logo

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next‐generation solutions in protein homeostasis, immuno‐oncology, epigenetics, immunology and neuro‐inflammation.